Publication: Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
Issued Date
2018-04-03
Resource Type
ISSN
2164554X
21645515
21645515
Other identifier(s)
2-s2.0-85041813086
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Human Vaccines and Immunotherapeutics. Vol.14, No.4 (2018), 900-905
Suggested Citation
Pornthep Chanthavanich, Kriengsak Limkittikul, Chukiat Sirivichayakul, Watcharee Chokejindachai, Weerawan Hattasingh, Krisana Pengsaa, Surachai Surangsrirat, Termsang Srisuwannaporn, Benjawan Kaewma, Sutee Yoksan, Gao Jun, Bai Zhumu Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children. Human Vaccines and Immunotherapeutics. Vol.14, No.4 (2018), 900-905. doi:10.1080/21645515.2017.1414763 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46024
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
Abstract
© 2018 The Author(s). Published with license by Taylor & Francis © 2018, © Pornthep Chanthavanich, Kriengsak Limkittikul, Chukiat Sirivichayakul, Watcharee Chokejindachai, Weerawan Hattasingh, Krisana Pengsaa, Surachai Surangsrirat, Termsang Srisuwannaporn, Benjawan Kaewma, Sutee Yoksan, Gao Jun, and Bai Zhumu. Summary: Inactivated mouse-brain-derived Japanese encephalitis vaccine has a worrisome safety profile and the live attenuated vaccine is unsuitable in immunodeficiency. This study aimed to evaluate the immunogenicity and safety of an inactivated chromatographically purified Vero-cell-derived JE vaccine (CVI-JE, Beijing P-3 strain) in children. 152 healthy Thai children, with an average (SD) age of 14.4 (3.8) months, received 3 doses of CVI-JE on days 0, 7–28, and one year. Homologous JE neutralizing antibody titers (NT) were measured. All subjects had seroprotection [geometric mean titer (GMT) 150] 28 days' post 2nd vaccination. The seroprotection rates at 1 year after primary series and and 1 month after the booster were 89.3% (GMT 49) and 100% (GMT 621), respectively. Local and systemic reactions–fever (17.6%), vomiting (8%), and poor appetite (5.3%)–were noted within 28 days' post-vaccination. All these symptoms were self-limited. Conclusions: CVI-JE is safe, immunogenic, and provided high NT.